MRK

NYSE · Pharmaceuticals

Merck & Co. Inc.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$146.87

-0.28 (-0.19%)

As of Sep 20, 9:30 PM ET ·

Financial Highlights (FY 2026)

Revenue

63.86B

Net Income

17.93B

Gross Margin

77.1%

Profit Margin

28.1%

Rev Growth

+3.1%

D/E Ratio

0.94

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	63.86B	61.92B	122.92B	97.21B
Gross Profit	49.22B	47.73B	73.70B	58.29B
Operating Income	20.84B	18.19B	24.40B	18.09B
Net Income	17.93B	15.65B	17.77B	14.84B
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%
Rev Growth	+3.1%	+3.1%	+3.7%	+0.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	87.52B	87.52B	126.52B	165.60B
Total Equity	93.31B	93.31B	163.18B	146.99B
D/E Ratio	0.94	0.94	0.78	1.13

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	23.83B	21.96B	40.31B	27.40B
Free Cash Flow	—	—	15.03B	9.18B